CSL Limited (CSLLY)
| Market Cap | 66.86B |
| Revenue (ttm) | 15.56B |
| Net Income (ttm) | 3.00B |
| Shares Out | n/a |
| EPS (ttm) | 6.17 |
| PE Ratio | 22.27 |
| Forward PE | 18.95 |
| Dividend | 1.36 (1.96%) |
| Ex-Dividend Date | Sep 10, 2025 |
| Volume | 36,574 |
| Average Volume | 78,900 |
| Open | 69.21 |
| Previous Close | 69.99 |
| Day's Range | 68.58 - 69.33 |
| 52-Week Range | 68.58 - 109.00 |
| Beta | 0.33 |
| RSI | 26.35 |
| Earnings Date | Aug 19, 2025 |
About CSL Limited
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascul... [Read more]
Financial Performance
In 2025, CSL Limited's revenue was $15.56 billion, an increase of 5.12% compared to the previous year's $14.80 billion. Earnings were $3.00 billion, an increase of 13.63%.
Financial StatementsNews
CSL Limited falls as layoffs overshadow FY25 results
CSL Limited (CSLLY) Q4 2025 Earnings Call Transcript
Full Year 2025 CSL Ltd Earnings Presentation Transcript
Full Year 2025 CSL Ltd Earnings Presentation Transcript
CSL Limited 2025 Q4 - Results - Earnings Call Presentation
The following slide deck was published by CSL Limited in conjunction with their 2025 Q4 earnings call.
Australian biopharma firm CSL posts 14% rise in annual profit
Australian biopharmaceutical company CSL reported 14% rise in annual earnings on Tuesday, driven by strong performance at its blood plasma business CSL Behring.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start
ANDEMBRY inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacks Once-monthly dosing reduced HAE attacks by a median of more than 99 percent and a l...
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading cause of kidney failure 1-3 NICE's recommendation is based on clinically meani...
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the treatment of IgA Nephropathy (IgAN) Decision follows positive recommendation f...
CSL Limited: Divergent Outlook For Its 2 Key Businesses
I maintain a Neutral view on CSL Limited due to the mixed prospects for its flu vaccine (Seqirus) and plasma therapy (Behring) segments. Read why I rate CMXHF as a hold.
CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)
ANDEMBRY® is a first-in-class monoclonal antibody treatment that inhibits activated Factor XII (FXIIa), the initiating factor in the HAE pathway, and offers the first pre-filled pen presentation enabl...
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
- KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional mRNA...
European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
- ANDEMBRY®, the first and only once-monthly treatment targeting factor XIIa to prevent attacks in HAE patients, inhibits plasma protein factor XIIa, which initiates the cascade of events leading to a...
Half Year 2025 CSL Ltd Earnings Presentation Transcript
Half Year 2025 CSL Ltd Earnings Presentation Transcript
CSL Limited 2025 Q2 - Results - Earnings Call Presentation
The following slide deck was published by CSL Limited in conjunction with their 2025 Q2 earnings call.
CSL Limited (CSLLY) Q2 2025 Earnings Call Transcript
CSL Limited (OTCQX:CSLLY) Q2 2025 Results Earnings Conference Call February 10, 2025 7:00 PM ET Company Participants Chris Cooper - Vice President and Head of Investor Relations Paul McKenzie - Chief ...
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
CSL Limited (OTC: CSLLY) and uniQure Inc (NASDAQ: QURE) announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of Hemgeni...
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
94 percent of patients eliminated factor IX prophylaxis and remained free of continuous prophylaxis through four years post-treatment Mean factor IX activity levels were sustained at near normal level...
CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE)
If approved, garadacimab will be the first and only once-monthly treatment inhibiting factor XIIa to prevent attacks in HAE patients – a community CSL has been serving for more than 40 years MARBURG, ...
New Data Presented at IDWeek 2024 Show Adjuvanted and High-Dose Influenza Vaccines are Comparable in Protecting Adults 65 Years of Age and Older Against Seasonal Influenza
Results of the first season of a randomized study showed adjuvanted and high-dose influenza vaccines did not differ in effectiveness against PCR-confirmed influenza. This is the first randomized study...
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Temporary marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial ST. GALLEN, Switzerland and SAN DIEGO, Oct. 17, 2024 /PRNewsw...
CSL Seqirus Presents Data at IDWeek 2024 Highlighting the Urgent Need to Increase Influenza Vaccination Rates and the Benefits of Cell-Based Influenza Vaccines
Analysis from a dynamic model showed the need to increase influenza vaccination rates in the U.S. to at least 45% to avoid saturation of hospital system resources, particularly in intensive care units...
GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE: GSK), Sanofi SA (NASDAQ: SNY) and Australian firm CSL Limited (OTC: CSLLY) to more than double the U.S. supply o...
CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Sixth BARDA Award in Response to Avian Influenza
CSL Seqirus has received a Biomedical Advanced Research and Development Authority (BARDA) award to complete the fill and finish process for additional pre-pandemic vaccines to further support the U.S....